Upsher Smith Labs Company Profile
✉ Email this page to a colleague
What is the competitive landscape for UPSHER SMITH LABS, and what generic alternatives to UPSHER SMITH LABS drugs are available?
UPSHER SMITH LABS has ninety-two approved drugs.
There are eight US patents protecting UPSHER SMITH LABS drugs.
There are seventeen patent family members on UPSHER SMITH LABS drugs in ten countries and one hundred and thirty-seven supplementary protection certificates in thirteen countries.
Summary for Upsher Smith Labs
| International Patents: | 17 |
| US Patents: | 8 |
| Tradenames: | 71 |
| Ingredients: | 65 |
| NDAs: | 92 |
Drugs and US Patents for Upsher Smith Labs
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upsher Smith Labs | OXANDROLONE | oxandrolone | TABLET;ORAL | 078033-001 | Mar 22, 2007 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Upsher Smith Labs | PROPAFENONE HYDROCHLORIDE | propafenone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212744-003 | Jun 25, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Upsher Smith Labs | ETHACRYNIC ACID | ethacrynic acid | TABLET;ORAL | 212417-001 | Feb 19, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Upsher Smith Labs | IRBESARTAN | irbesartan | TABLET;ORAL | 200461-003 | Sep 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Upsher Smith Labs | MOXIFLOXACIN HYDROCHLORIDE | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212616-001 | Feb 10, 2021 | AT1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Upsher Smith Labs | SOTALOL HYDROCHLORIDE | sotalol hydrochloride | TABLET;ORAL | 075366-001 | May 1, 2000 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Upsher Smith Labs
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | 6,440,392 | ⤷ Sign Up |
| Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | RE43580 | ⤷ Sign Up |
| Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | RE40812 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for UPSHER SMITH LABS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg | ➤ Subscribe | 2015-12-24 |
| ➤ Subscribe | Nasal Spray | 200 IU/spray | ➤ Subscribe | 2006-03-29 |
International Patents for Upsher Smith Labs Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2014143380 | ⤷ Sign Up |
| European Patent Office | 2968177 | ⤷ Sign Up |
| Singapore | 11201604788U | ⤷ Sign Up |
| South Korea | 102072618 | ⤷ Sign Up |
| South Korea | 101674509 | ⤷ Sign Up |
| Canada | 2857286 | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Upsher Smith Labs Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0473687 | SPC/GB98/030 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204 |
| 3494972 | 301277 | Netherlands | ⤷ Sign Up | PRODUCT NAME: DOLUTEGRAVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT, WAARONDER DOLUTEGRAVIRNATRIUM, EN LAMIVUDINE; REGISTRATION NO/DATE: EU/1/19/1370 20190703 |
| 0382526 | 19675032 | Germany | ⤷ Sign Up | PRODUCT NAME: LAMIVUDINE, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH GEEIGNETEN SALZES; NAT. REGISTRATION NO/DATE: EU/1/96/015/001-002 19960808 FIRST REGISTRATION: CH 53662 53663 19960228 |
| 1175904 | 2007C/048 | Belgium | ⤷ Sign Up | PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826 |
| 1519731 | 13C0067 | France | ⤷ Sign Up | PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215 |
| 0350733 | 11/2000 | Austria | ⤷ Sign Up | PRODUCT NAME: MOXIFLOXACIN, DESSEN PHARMAZEUTISCH VERWENDBARE HYDRATE UND SAEUREADDITIONSSALZE, DESSEN ALKALI-ERDALKALI-SILBER- UND GUANIDINIUMSALZE, SOWIE DESSEN C1 - C4 ALKYL- ODER; NAT. REGISTRATION NO/DATE: 1-23494, 1-23495, 1-23496 20000215; FIRST REGISTRATION: DE 45263.00.00 19990621 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
